Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00104403 · ClinicalTrials.gov registry record · Phase 2
Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 722
- Enrollment target
NCT00104403 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 722 participants.
The verdict
NCT00104403, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 722 participants
- Enrollment target
Study Summary
This study was designed to assess the safety and efficacy of different dosages and administration schedules of an investigational agent administered over 3 days when added to standard therapy used in the prevention of chemotherapy-induced nausea and vomiting in cancer patients. Subjects will be asked to complete daily diaries while on study medication. In addition subjects will be required to return to the investigational site several times during the course of the study for follow up safety assessments which may include blood samples for hematology and chemistry evaluations as well as physical exams. A final assessment will be preformed on study Day 20-30 at which time the subject will complete the study.
Interventions
- DRUG Dexamethasone
- DRUG GW679769
- DRUG Ondansetron Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 722 participants |
| Start Date | 2004-12 |
| Est. Completion | 2006-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00104403
The ClinicalTrials.gov registry entry for NCT00104403 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 722 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT00104403 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00104403 about?
NCT00104403 is a clinical study titled "Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy". This study was designed to assess the safety and efficacy of different dosages and administration schedules of an investigational agent administered over 3 days when added to standard therapy used in the prevention of chemotherapy-induced nausea and vomiting in cancer patients. Subjects will be aske...
What is the current status of trial NCT00104403?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 722 participants. The study started on 2004-12. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00104403?
The interventions under investigation include: Dexamethasone (DRUG), GW679769 (DRUG), Ondansetron Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00104403?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.